First‐in‐human, phase I, randomized, safety, pharmacokinetic, food‐effect and pharmacodynamic study of a tyrosine kinase 2/Janus kinase 1 inhibitor, SDC‐1801

Chris Brearley, Sam Francis, John Reader, Judi Proctor · 2026

Read First‐in‐human, phase I, randomized, safety, pharmacokinetic, food‐effect and pharmacodynamic study of a tyrosine kinase 2/Janus kinase 1 inhibitor, SDC‐1801 by Chris Brearley, Sam Francis, John Reader, Judi Proctor (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13619091.txt.

Description

Chris Brearley and three colleagues report a 2026 first-in-human trial of SDC-1801, an oral drug that blocks two signaling enzymes linked to autoimmune disease. Ninety-five healthy adults took part in a randomized phase I study. Early parts tested single and repeated doses against placebo, while a later part checked how food changed absorption of the drug.

No deaths or treatment-related serious events occurred, and no side effect was severe, with unrelated headache reported most often. Blood levels peaked a few hours after dosing and the drug stayed in the body long enough to support once- or twice-daily use. Markers of inflammation fell as exposure rose, which the authors read as evidence that the drug engaged both of its targets.

Catalog record

CREATORChris Brearley, Sam Francis, John Reader, Judi Proctor
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE50470
LICENSEhttps://creativecommons.org/licenses/by/4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/article/MED/PMC13619091

Browse the full library · About the Tower of Babel